New Evidence Early Tx Improves Preclinical MS Outcomes New Evidence Early Tx Improves Preclinical MS Outcomes

The disease-modifying drug teriflunomide reduces the risk of developing clinical multiple sclerosis by 72% in radiologically isolated syndrome.Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news